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Background:
Leukemia is a type of hematologic malignancy that originates 
in the bone marrow and leads to accumulation of immature 
hematopoietic cells with clonal origin. These leukemic cells 
can out-compete normal blood cells, replacing them in the 
bone marrow and spreading to extramedullary sites, and 
thus interfering with the normal function of the hematological 
tissue. The Canadian Cancer Society estimates 5000 new 
cases of leukemia for 2011, with approximately 2500 deaths.
(1)
Leukemia is a heterogeneous disease that can be subdivided 
according to the cell lineage affected (myeloid or lymphoid) 
and the degree of differentiation of leukemic cells. More re-
cent classifications by the World Health Organization also 
incorporate pathologic and genetic markers, achieving more 
biological significance.(2) 
Chromosomal aberrations and leukemogenesis: delin-
eating causes and effects.
Our knowledge of leukemogenesis is greatly influenced by 
the discovery of recurring chromosomal aberrations and/or 
gene mutations capable of malignant transformation of cells.
(3) The target cell for these mutations is not always known, 
but increasing evidence indicates that leukemias originate 
in hematopoietic stem cells (HSCs) that are transformed 
into leukemia stem cells (LSC) by these chromosomal ab-
errations. LSCs and HSCs share two important character-
istics, self-renewal and differentiation of new hematopoietic 
tissue. The clonogenic nature of leukemias is similar to that 
observed in normal hematopoiesis, and only a small specific 
subset of leukemic cells, LSCs, are capable of indefinite pro-
liferation, as seen only for HSCs.(4) 
If we consider HSCs as the cells of origin for most leukemias, 
we can better comprehend the high incidence of chromo-
somal aberrations present in this type of cancer.  In a normal 
organism HSCs are usually quiescent and cycle very slowly; 
this is a protective mechanism to minimize DNA replication 
errors and the generation of toxic metabolic subproducts. 
However, quiescence of HSCs also presents a disadvan-
tage. Once DNA damage does occur, specifically DNA dou-
ble strand breaks (DSB), these cells must repair the lesions 
through the non-homologous end joining (NHEJ) pathway. 
NHEJ is an error-prone, mutagenic pathway that often caus-
es chromosomal aberrations.(5) Given the self-renewal prop-
erty of HSCs, mutations can be transmitted and accumulat-
ed, giving rise to LSCs with a high frequency of chromosomal 
aberrations; in fact, most recurring translocations in leukemia 
display a NHEJ repair signature.(6) 
Most chromosomal translocations in leukemias occur in 
chromosomal regions where the DNA is more susceptible 
to double strand breaks. These susceptibility regions can 
be characterized by several chromatin structural elements, 
including topo II DNA cleavage sites, DNase I hypersensi-
tive sites, scaffold/matrix attachment regions (S/MAR) and 
retrotransposon regions (LINE and SINE).(6) Chromosomal 
position within the nucleus also influences the frequency of 
translocations. It is likely that loci localized in close proximity 
inside the nucleus will more frequently translocate in cases of 
DSBs.(7) Finally, for these translocations to lead to transfor-
mation, they must generate fusion proteins that promote an 
advantage to the cell. 
Thousands of chromosomal translocations have been detect-
ed in leukemia cells.(8) Most of these fall within two catego-
ries: type I mutations promote increased proliferation or sur-
vival, and type II mutations impair differentiation or enhance 
self-renewal. At least one mutation of each type seems to be 
necessary for leukemogenesis.(9) Leukemic chromosomal 
translocations generate chimeric fusion proteins, and many 
of these fusion proteins have similar characteristics: they lo-
calize to the nucleus, affect transcriptional regulation, contain 
a DNA binding domain and cause epigenetic modifications.
(10) 
In fact, epigenetic changes are a common occurrence in 
most acute leukemias.(3) If we consider that during normal 
hematopoiesis a complex program of epigenetic modifica-
tions takes place, it becomes clearer how altering epigenetic 
modifications can affect cell differentiation and self-renewal 
leading to leukemogenesis.(11) HOX genes are a prime ex-
ample of epigenetic regulation. The pattern of HOX expres-
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sion in cells is epigenetically regulated and inherited; each 
cell in the hematopoietic differentiation continuum displays 
a specific pattern of HOX genes expressed. More primitive 
hematopoietic cells have higher levels of HOX expression, 
as cells differentiate and lose their proliferative capabilities, 
HOX expression decreases until it becomes absent in com-
pletely differentiated cells. Overexpression of numerous 
HOX genes can induce leukemogenesis, in several cases 
changes in their expression levels are a result of histone 
modifications in the 5’ HOXA gene.(12) 
Nucleoporin genes and cancer.
To date, the literature has revealed five nucleoporins involved 
in carcinogenesis, Tpr, Nup88, Nup98, Nup214(13) and 
Nup358.(14) Nup88 expression is up-regulated in several 
cancers, specially carcinomas. Increase in its protein levels 
is thought to deregulate NF-kB nuclear transport maintaining 
it constantly activated.(15) The remaining 4 nucleoporins are 
involved in carcinogenic gene fusions.
Tpr gene fusions with Met and NTrk1 have been described in 
gastric cancers and papillary thyroid carcinomas, respective-
ly. In both cases the N-terminal coiled-coil domain of Tpr is 
juxtaposed with the tyrosine kinase domain of the fusion part-
ner. This leads to dimerization independent of ligand, and to 
constitutive activation of kinase activity, causing deregulated 
signaling that leads to carcinogenesis.(13) A similar carcino-
genic mechanism is seen in Nup358 fusions. In inflammato-
ry myofibroblastic tumors, the N-terminal leucine zipper of 
Nup358 is fused to the tyrosine kinase domain of ALK, also 
leading to deregulated kinase activation.(16) 
Gene fusion of NUP214 and NUP98 play a role in leuke-
mogenesis. NUP214 gene fusions with ABL also promote 
constitutive kinase activation in T-ALL. The kinase domain 
of ABL is fused to the N-terminal coiled-coil motif of Nup214. 
Interaction between this motif and nup88 allows localization 
of the fusion to the nuclear pore complex (NPC), bringing 
the kinase domains to sufficient proximity for constitutive 
activation.(17) In very rare cases Nup214 also translocates 
with SET and DEK in T-ALL and AML, respectively. In these 
cases almost the full length SET or DEK protein is fused to 
the C-terminal FG repeat of Nup214.(13) SET-NUP214 can 
interact with HOXA gene promoters leading to their expres-
sion. HOXA expression only occurs in the earliest T-cell pre-
cursor, so the fusion blocks T cell differentiation.(18) DEK-
NUP214 fusions seem to increase overall protein translation 
specifically in myeloid cells, possibly facilitating carcinogen-
esis.(19) SET and DEK are two histone interacting proteins 
that perform opposing roles in the regulation of access to 
chromatin. SET promotes and DEK restricts accessibility to 
chromatin by the transcriptional machinery.(20) It is possible 
that NUP214 translocation with these genes affects the bal-
ance between the two chromatin modifiers. 
The NUP98 gene is fused to a wide range of partner genes, 
resulting in several hematopoietic disorders, especially acute 
myeloid leukemia (AML). 
NUP98 translocations in leukemias.
All NUP98 translocations described thus far generate a chi-
meric fusion protein that retains the N-terminal portion of 
Nup98 and the C-terminal of the fusion partner. Most chro-
mosomal breaks take place between exons 11 and 13 of the 
NUP98 gene.(21) Interestingly, an enrichment of DNAse I 
hypersensitivity sites and a strong prediction of S/MAR are 
present in this region, corroborating its increased susceptibil-
ity to translocations, as seen in figure 1 below.
Figure 1: NUP98 gene chromatin structure. A – UCSC genome 
browser(52) tracks displaying NUP98 gene structure (most common-
ly translocated region, exons 11 to 14, marked) and DNAse I hyper-
sensitivity sites. B – S/MAR enrichment on NUP98 gene, defined by 
MARFinder.(53)
The N-terminal portion of Nup98 (conserved in fusions) con-
tains FG/GLFG repeats flanking a coiled-coil Rae1 interac-
tion site (Fig. 2A). Even though a third of all nucleoporins 
contain FG repeats, Nup98 is the only GLFG repeat contain-
ing nucleoporin in humans.(22) At nuclear pore complexes 
(NPC), Nup98 interacts with transport molecules, mediating 
traffic through the NPC. The N-terminal of Nup98 interacts 
with XPO1, facilitating export of specific proteins from the nu-
cleus,(23) and with TAP and Rae1, promoting mRNA export 
to the cytoplasm.(24) 
Nup98 can also be found away from the NPC, dispersed 
through the nucleoplasm and in intranuclear structures called 
GLFG bodies (Fig. 2B).(25) In embryonic Drosophila cells, 
the intranuclear pool of Nup98 interacts with transcription-
ally active genes and changes to the level of Nup98 present 
can modulate their expression, especially in developmental 
genes.(26) In human cells, the N-terminal GLFG repeats of 
nup98 have been shown to interact with histone acetyl trans-
ferases and histone deacetylases.(27, 28) 
At least 27 different genes have been found translocated with 
NUP98 in leukemic patients (Fig. 2C). Most of these gene 
fusions lead to myeloid malignancies (AML, CML, MDS); 
however, six fusions have so far been identified in T-ALL pa-
tients. Nup98 fusions are rare (approximately 2% AML cas-
es) however, they usually indicate a poor prognosis. Over 
half of Nup98 fusions are detected in patients under 20 years 
of age and only 25% occur in patients with therapy related 
malignancies.(21) The karyotype of patients with Nup98 fu-
sions is usually simple, with no more than 3 chromosomal 
aberrations,(29) indicating a strong transformation potential 
for the fusions and arguing against an increase in genetic 
instability.
Nup98 fusion partners can be divided into homeodomain 
(HD) and non-HD containing proteins. Fusions with HD con-
taining proteins always maintain the N-terminal GLFG do-
main of Nup98 fused in frame to the C-terminal HD of the 
partner gene.(30) NUP98-HOXA9 was the first fusion detect-
ed in an AML patient(31, 32) and it is currently the best-char-
acterized Nup98 translocation. All non-HD containing partner 
genes encode putative coiled-coil motifs,(33) a domain usu-
ally involved in mediating protein-protein interactions. Chro-
matin recognition domains, such as plant homeodomain zinc 
fingers (PHD), are also recurrent in non-HD Nup98 fusion 
partners.(34)
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Figure 2: Nup98 and Nup98 fusions. A – Nup98 protein domains and known interactions, B – Nup98 localization in 293T cells visualized by 
immunofluorescence microscopy and C – Diagram of know Nup98 gene fusions and their characteristics.
So far, few common denominators have been identified when 
it come to the mechanism by which Nup98 fusions may lead 
to leukemogenesis. Characterizing their effects in altered 
gene expression indicates a few common targets: fusions 
of Nup98 with NSD1, KDM5A, PHF23, HOXA9, HOXD13, 
PRRX1, HHEX and DDX10 seem to increase the expression 
of HOXA cluster genes; NSD1, HOXA9 and DDX10 fusions 
also up-regulate the Hox co-factor Meis1; and HOXA9 or 
HOXD13 translocations increase the expression of interferon 
responsive genes.(21) A putative mechanism for how these 
fusions may alter gene expression has only been described 
for PHD domain containing translocations (NSD1, KDM5A 
and PHF23). These fusions seem to bind HOXA gene pro-
moters (through the PHD finger) and recruit histone acety-
lases CBP/p300 (via GLFG domain) that modify chromatin 
into a transcriptionally active state.(34, 35) Nup98 fusions 
with HD containing proteins are assumed to act directly as 
transcription factors; they can in some cases collaborate with 
Meis1, a Hox co-factor that increases specificity and binding 
to target DNAs.(36)
Preliminary analysis:
Commonalities among NUP98 translocation partner 
genes.
Performing bioinformatics analysis of Nup98 fusion partner 
genes, a few recurrent themes are uncovered (Tab. I). Inves-
tigating the interaction profile of these partner proteins we 
notice that chromatin and/or DNA binding is a characteris-
tic of 75% of them. The partner genes usually display direct 
DNA interaction or recognition of histone post-translational 
modifications, with 50% of all fusion partners working as 
transcriptional regulators. Separating Nup98 fusions leading 
to myeloid malignancies from those causing T-ALL, an even 
clearer picture appears: over 95% of myeloid related fusions 
can interact with DNA/chromatin, with over 2/3 of them act-
ing as transcriptional regulators. T-ALL related fusions show 
no transcriptional regulators among partner genes and only 
one of them can interact with DNA/chromatin, likely pointing 
towards distinct molecular mechanisms for myeloid and lym-
phoid causing Nup98 fusions.
Evaluating biological processes affected by Nup98 fusion 
partner genes, we determine that almost 60% of them par-
ticipate in embryonic regionalization and development, with 
over half being involved in transcription. Other biological pro-
cesses over-represented among the fusion partners are reg-
ulation of cell proliferation, cell differentiation and chromatin 
modification (Tab. I). Interestingly, in Drosophila cells, Nup98 
itself seems to regulate the transcription of developmental 
and cell cycle genes.(26)
The data above indicate that Nup98 fusions might function as 
rogue transcriptional regulators, especially in myeloid malig-
nancies. It is possible that these fusions can affect gene ex-
pression acting directly as transcription factors (TF), altering 
histone modifications or deregulating other TFs.
Hypothesis:
The goal of this project is to define common mechanisms 
by which these different Nup98 fusions lead to malignancy. 
Based on the background and on the preliminary analysis 
provided above we hypothesize that Nup98 fusions, espe-
cially those leading to AML, might function as rogue tran-
scriptional regulators, and that their deregulated target genes 
might impair cell differentiation and increase self-renewal, 
setting the stage for malignant transformation and acute my-
eloid leukemia. 
In this project, we propose to study the changes in gene 
expression caused by Nup98 translocations in bone mar-
row cells. Using data integration of previously published mi-
croarray experiments we will compare the effects of different 
Nup98 fusion proteins in the gene expression profile of bone 
marrow cells, leading to the discovery of specific pathways 
responsible for the disease phenotype. These relevant path-
ways can indicate key drug targets for this malignancy, and 
drug responses can be modeled in the existing networks, 
aiding in the development of new therapies for this disease. 
Materials and Methods:
In order to further explore the possible role of Nup98 fusions 
as rogue transcriptional regulators, I collected microarray 
experiments of bone marrow cells transformed with different 
fusions for analysis. In order for this multi-experiment analy-
sis to present biological significance, I only used results from 
experiments performed in similar conditions, ending up with 
4 directly comparable sets: NUP98-HHEX, NUP98-HOXA9, 
NUP98-HOXA10, NUP98-HOXD13(37, 38).
All fusions were transduced into adult mice bone marrow 
cells using the retroviral vector MSCV-IRES-GFP (the emp-
ty vector was used as control), cells were FACS sorted be-
fore mRNA purification, target preparation and hybridization 
to Affymetrix Mouse Genome 430A Arrays. The raw (.CEL) 
file of each experiment was RMA (robust multichip average) 
normalized(39) and cross-study normalization was achieved 
using ComBat,(40) an empirical bayes method. The ANOVA 
statistical test (p<0.05) was used in AltAnalyze(39) to identi-
fy genes differentially expressed in control vs. Nup98 fusion 
samples, producing a list of genes whose expression was 
similarly affected by all Nup98 fusion proteins.
Functional annotation analysis of all gene lists was per-
formed through the Database for Annotation, Visualization 
and Integrated Discovery (DAVID)(41) v6.7. Distant regula-
tory elements of co-regulated genes, such as transcription 
factor binding sites and CpG islands, were identified using 
DiRE.(42) Finally, functional protein association networks 
were inferred using STRING(43) version 9.0 and were im-
ported into Cytoscape(44) for formatting. 
Results and Discussion:
The expression of several genes is similarly altered in 
the presence of different Nup98 fusions.
Analyzing the genes whose expression was affected by all 
Nup98 fusions similarly, we see enrichment of a few bio-
logical processes: embryonic development, immune sys-
tem formation and chromatin organization (Fig. 3A and Tab. 
S1). Evaluating only those genes whose expression was 
increased in the presence of all NUP98 translocations, we 
see enrichment for regulation of transcription, cell prolifera-
tion and immune system development (Fig. 3B). On the other 
hand, genes with decreased expression in the presence of 
Nup98 fusions are overrepresented for embryonic develop-
ment, RNA processing and chromatin modification (Fig. 3C). 
These changes in the expression profile of genes involved in 
chromatin organization and modification can be correlated to 
the know epigenetic deregulation occurring in leukemic cells, 
especially as has been described for cells containing NUP98 
translocations.(21) An increase in the expression of cell pro-
liferation genes can also explain the expansion in the number 
of these LSCs. They abandon quiescence, as seen in HSCs, 
and actively proliferate in a deregulated manner, contributing 
to malignancy.
Genes with altered expression in the presence of NUP98 
fusions are regulated by similar transcription factors.
Mapping the regulatory regions and transcription factor bind-
ing sites (TFBS) present in the deregulated genes, we can 
see that up and down-regulated genes present several regu-
latory regions in common, and 38 transcription factor binding 
site are enriched in both sets of genes (Tab. 2). 
These transcription factors play relevant roles in cell cycle 
regulation, embryonic development, hematopoiesis, apopto-
sis and chromatin modifications (Fig. 4). They form a highly 
interconnected network,(43) indicating protein-protein inter-
actions and transcriptional regulation among themselves 
(Fig. 5). Networks of TFs regulating genes with increased ex-
pression or genes with decreased expression are less inter-
connected than that of TFs that are present in both; however, 
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Total AML ALL
DNA/Chromatin binding 0 0 0 1 1 1 1 1 1 1 1 1 0 1 0 1 1 1 1 1 1 0 1 1 1 1 1 77.78% 95.24% 16.67%
Transcription regulator 0 0 0 1 0 1 1 1 1 1 1 1 0 1 0 1 1 0 1 1 0 0 1 0 0 0 0 51.85% 66.67% 0.00%
Homeobox 0 0 0 1 0 1 1 1 1 1 1 1 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 35.71% 40.00% 0.00%
Coiled-coil 62.96% 52.38% 100.00%
Zinc finger PHD 0 0 0 0 0 0 0 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 0 0 0 1 17.86% 20.00% 0.00%
Embryonic regionalization 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 59.26% 57.14% 66.67%
Cell differentiation 1 1 1 1 1 18.52% 23.81% 0.00%
Regulation of cell proliferation 1 1 1 1 1 1 22.22% 19.05% 33.33%
Transcription 1 1 1 1 1 1 1 1 1 1 1 1 1 1 51.85% 47.62% 66.67%
Chromatin modification 1 1 1 1 14.81% 9.52% 33.33%
Myeloid 77.78%
Lymphoid 22.22%
Nup98 fusion genes
Biological 
Process
Interaction
Protein 
domains
Lineage
Table I: Characteristics of Nup98 fusion partner genes.
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up reg genes down reg genes up reg genes down reg genes
cebpa 12606
cebpb 12608
CMAF maf 17132 4.41% 1.43% 0.0024 0.00896
CRX crx 12951 2.94% 1.08% 0.00037 0.00329
DEC Bhlhe40 20893 7.35% 2.87% 0.07077 0.00621
E2A tcf3 21423 8.82% 7.17% 0.02206 0.00341
e2f1 13555
tfdp1 21781
e2f1 13555
tfdp1 21781
rb1 19645
e2f4 104394
tfdp1 21781
FOXJ2 foxj2 60611 7.35% 1.79% 0.13281 0.01915
FOXO4 foxo4 54601 7.35% 1.08% 0.00184 0.00184
GC 16.18% 19.35% 0.03808 0.13548
gcm2 107889
gcm1 14531
GRE 1.47% 1.08% 0.0136 0.00197
HFH1 foxq1 15220 2.94% 0.36% 0.01454 0.00205
HIF1 hif1a 15251 11.76% 9.68% 0.02061 0.04876
hnf1a 21405
hnf1b 21410
IK1 ikzf1 22778 4.41% 2.15% 0.02509 0.00403
Nr1h2 22260
nr1h3 22259
MYB myb 17863 7.35% 2.51% 0.02941 0.00044
MYC myc 17869 1.47% 2.87% 0.01418 0.02151
MYOGENIN myog 17928 7.35% 6.09% 0.05285 0.00515
NERF elf2 69257 8.82% 5.02% 0.09816 0.01944
NFKAPPAB50 nfkb1 18033 7.35% 2.51% 0.16176 0.00659
NFKB rela 19697 8.82% 6.81% 0.02105 0.06719
nfia 18027
nfib 18028
nfic 18029
nfix 18032
P53 trp53 22059 8.82% 1.43% 0.14366 0.00409
PAX pax1 18503 5.88% 2.51% 0.04559 0.01687
PAX9 pax9 18511 4.41% 2.87% 0.01665 0.01093
RSRFC4 mef2a 17258 2.94% 0.72% 0.00126 0.00905
srebf1 20787
srebf2 20788
STAT stat1 20846 7.35% 2.51% 0.0432 0.01443
TAL1 tal1 21349 5.88% 2.15% 0.06324 0.00225
TCF4 tcf4 21413 2.94% 2.15% 0.04403 0.01667
TEL2 telo2 71718 1.47% 2.15% 0.00729 0.01726
TST1 pou3f1 18991 1.47% 1.08% 0.01556 0.0121
USF2 usf2 22282 1.47% 2.87% 0.00023 0.02222
WT1 wt1 22431 14.71% 6.45% 0.03808 0.03055
ZF5 zfp161 22666 27.94% 23.30% 0.08507 0.13499
OCT4 pou5f1 18999 2.94% 1.08% 0.01838 0.00753
HNF1
Common TFs
NFY
SREBP
CpG islands
glucocorticoid res. elem.
Occurence
13.24% 4.66%
5.88%
Symbol Gene ID
CEBP
E2F1DP1
LXR
E2F1DP1RB
E2F4DP1
GCM
Importance
8.82% 4.66% 0.01544 0.0459
0.03602
0.003240.066552.15%5.88%
5.88% 2.87% 0.03318 0.01098
2.87%5.88%
7.35% 4.30% 0.06147
0.03174 0.00453
0.01450.036762.87%
0.013560.035292.51%8.82%
7.35% 2.15% 0.07146 0.01984
0.002290.00147
Table 2: Transcription factors with TFBS enriched in genes with deregulated expression in the presence of nup98 fusions.
Figure 3: GO annotation biological process enrichment A) all 
genes differentially expressed; B) up-regulated genes; C) down-reg-
ulated genes in the presence of Nup98 fusion proteins.
each network contains at least one module of a few highly 
interconnected TFs (Fig. S1 and S2).
Some of these transcription factors are known to also be 
deregulated in other types of leukemia.
More in-depth analysis of the role of a few of the TFs puta-
tively regulating genes with altered expression in cells bear-
ing NUP98 translocations can uncover possible novel mech-
anisms by which these fusions may lead to leukemogenesis. 
Wilms Tumor 1 (WT1) is one of the most enriched TFBS in up 
and down regulated genes. WT1 is a TF with expression re-
stricted to hematopoietic progenitor cells in the bone marrow 
with a role in their self-renewal. Mutations in WT1 indicate a 
worse prognosis in acute leukemias and can be found in ap-
proximately 10% of AML cases.(45) This transcription factor 
can work as both a tumor suppressor and an oncogene, and 
it can enhance or repress transcription of its target genes 
(such as MYC and BCL-2) depending on cellular conditions.
(46) WT1 and N-terminal Nup98 (present in fusions) both in-
teract with CBP, providing an interesting putative mechanism 
on how Nup98 fusions might be affecting this TF and its tar-
gets without affecting its expression level. 
As another example, CEBPA appears as an important reg-
ulatory TF in genes deregulated by Nup98 fusions. Interest-
ingly its own expression is reduced nearly 2 fold in Nup98 
fusion expressing cells. Decreased CEBPA expression in BM 
cells decreases differentiation and increases proliferation of 
myeloid progenitors leading to leukemia. Another leukemic 
fusion, AML1-ETO, has also been shown to down-regulate 
CEBPA expression, and CEBPA mutations that abrogate its 
function or generate dominant negatives have also been de-
scribed as leukemogenic.(47) 
TFBS for MYC are also overrepresented in this deregulated 
gene set, albeit to a lesser extent. MYC expression increas-
es 40% in the presence of Nup98 fusions, similarly to what 
is observed with several other leukemic chromosomal aber-
rations (AML1-ETO, PML-RARA, PLZF-RARA, FLT3-ITD) 
shown to induce c-myc activation. Overexpression of c-myc 
alone in BM cells can quickly induce fatal AML.(48)
Figure 4: GO annotation biological process enrichment for all 
TFs with TFBS enriched in genes differentially expressed in the pres-
ence of Nup98 fusion proteins.
The identified transcription factor network is highly sim-
ilar to the network of transcription factors regulating 
growth arrest and differentiation in human myeloid cells.
Given the above results, we can hypothesize that these 
NUP98 translocations are deregulating transcription factors 
that control differentiation and self-renewal in primitive he-
matopoietic cells. The network of transcription factors reg-
ulating growth arrest and differentiation in a human myeloid 
cell line has already been described.(49) Superposing the 
microarray results obtained above into this previously pub-
lished network (Fig. 6), we notice that over 80% of the TFs 
thought to regulate growth arrest and differentiation have 
decreased expression in cells containing Nup98 fusions. Ad-
ditionally, 70% of the TFs represented in this network have 
enriched TFBS in genes with deregulated expression upon 
NUP98 translocations. This reinforces the idea that Nup98 
fusions can deregulate key TFs in myeloid cells, leading to 
a cascade of changes in their gene expression profile that 
ultimately disrupts differentiation and proliferation, promoting 
leukemogenesis.
Enrichment of CpG islands in the promoter region of 
genes with deregulated expression further indicates epi-
genetic deregulation in the presence of Nup98 fusions.
A final interesting observation is the enrichment of CpG is-
lands in the promoters of genes with deregulated expression 
in Nup98 fusions, indicating an important role for epigenetic 
changes in their altered expression. Epigenetic regulation of 
gene expression is a hallmark of hematopoiesis, and several 
leukemic translocations have been shown to alter transcrip-
tion by altering epigenetic markers in their target genes.(3) 
HOX genes are an example of this epigenetic regulation and 
they are highly enriched for CpG islands in humans.(50) Sev-
eral Nup98 fusions promote HOX genes up-regulation,(21) 
some of them have been shown to alter histone post transla-
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tional modifications in the HOX locus,(34, 35) and it is possi-
ble that Nup98 fusions may also lead to epigenetic deregula-
tion affecting DNA methylation or histone modifications in the 
CpG islands identified in deregulated genes. 
As well as DNA methylation, CpG islands in gene promoters 
can be silenced by polycomb group proteins.(51) In mouse 
hematopoietic progenitors NUP98-KDM5A fusions bind the 
promoters of HOXA6-A10, this stops polycomb complex pro-
teins from silencing them, maintains H3K4me3 and acetyl-
ated histones in their promoter, and leads to increased ex-
pression of these genes.(34) Similarly, NUP98-NSD1 binds 
the promoters of HOXA7 and HOXA9, leading to histone 
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Figure 5: Protein-protein interaction network of TFs with TFBS enriched in genes differentially expressed in Nup98 translocations.
acetylation (p300 recruitment by Nup98’s N-terminal) and 
H3K36me3 (NSD1 C-terminal function) that increase gene 
expression.(35) It’s possible that other Nup98 fusion proteins 
may have similar mechanisms of epigenetic deregulation.
Concluding remarks:
The project described here aims at improving our under-
standing of how NUP98 translocations lead to leukemia. 
Based on previous literature and the results presented we 
can see that most Nup98 fusion partners provide a DNA/
chromatin interacting interface to these fusion proteins. This 
leads to the deregulation of sets of genes that increase the 
proliferation of these cells, as well as to the deregulation 
of genes that alter epigenetics. The genes with altered ex-
pression in the presence of Nup98 fusions are regulated by 
similar transcription factors, and these form a highly inter-
connected network. Part of this regulatory transcription factor 
network is itself down-regulated and very similar to the net-
work of transcription factors regulating growth arrest and dif-
ferentiation in human myeloid cells. It’s likely therefore, that 
these Nup98 fusions act as rogue transcriptional regulators, 
affecting mainly cell differentiation and self-renewal. 
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Table S1: Genes with altered expression in the presence of Nup98 fusions.
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Figure S1: Protein-protein interaction network of TFs with TFBS enriched in genes with up-regulated expression in Nup98 translocations.
October 2012 13
Figure S1: Protein-protein interaction network of TFs with TFBS enriched in genes with up-regulated expression in Nup98 translocations.
